ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
Clinical trial NCT05079022 · UNKNOWN
Trial details
- NCT number
- NCT05079022
- Sponsor
- Peking University People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-01
- Primary completion
- 2023-03-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.